Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252810 · ClinicalTrials.gov registry record · Phase 2
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
A Phase 2 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 284
- Enrollment target
NCT01252810 is a Phase 2 study that has completed, run by GE Healthcare. The registered enrollment target is 284 participants.
The verdict
NCT01252810, a Phase 2 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 284 participants
- Enrollment target
Study Summary
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class III or greater, who are referred for a coronary catheterization procedure with or without PCI.
Interventions
- DRUG GE-145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 284 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01252810
The ClinicalTrials.gov registry entry for NCT01252810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GE-145 is the first listed.
NCT01252810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01252810 about?
NCT01252810 is a clinical study titled "Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure". To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus (DM) requiring drug therapy, or congestive heart failure (CHF) NYHA Class...
What is the current status of trial NCT01252810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 284 participants. The study started on 2010-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01252810?
The interventions under investigation include: GE-145 (DRUG).
Who is sponsoring clinical trial NCT01252810?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.